Table 2. Antifungal susceptibility test results for selected species of Candida isolated during the study period.
| Species (n) | Antifungal agent | MIC range(µg/ml) | MIC50(µg/ml) | MIC90(µg/ml) | No. (%) of resistant or SDD isolates | |
| CLSI | EUCAST | |||||
| C. albicans (167) | Amfotericin B | 0,016–1 | 0,5 | 0,5 | na | 0 |
| Caspofungin | 0,002–0,25 | 0,06 | 0,125 | 0 | Na | |
| Fluconazole | 0,125–256 | 0,25 | 1 | 2 (1,3) | 6 (3,6) | |
| Itraconazole | 0,006–256 | 0,125 | 0,25 | 18 (11,9) | Na | |
| Voriconazole | 0,002–256 | 0,003 | 0,016 | 2 (1,3) | 6 (3,6) | |
| C. parapsilosis (98) | Amfotericin B | 0,008–1 | 0,5 | 0,5 | na | 0 |
| Caspofungin | 0,03–1 | 0,5 | 1 | 0 | Na | |
| Fluconazole | 0,06–8 | 1 | 4 | 0 | 2(2) | |
| Itraconazole | 0,006–0,5 | 0,125 | 0,25 | 23 (26,4) | Na | |
| Voriconazole | 0,006–0,125 | 0,016 | 0,06 | 0 | 0 | |
| C. glabrata (33) | Amfotericin B | 0,03–1 | 0,05 | 1 | na | 0 |
| Caspofungin | 0,006–0,25 | 0,06 | 0,125 | 0 | Na | |
| Fluconazole | 0,5–256 | 16 | 32 | 27 (81,8) | 31 (93,9) | |
| Itraconazole | 0,125–16 | 1 | 8 | 29 (96,6) | Na | |
| Voriconazole | 0,006–8 | 0,25 | 1 | 3 (9,6) | 16(48,5) | |
| C. tropicalis (23) | Amfotericin B | 0,06–2 | 0,5 | 1 | na | 0 |
| Caspofungin | 0,016–0,16 | 0,03 | 0,125 | 0 | Na | |
| Fluconazole | 0,25–256 | 1 | 8 | 3 (14,3) | 6 (26) | |
| Itraconazole | 0,125–16 | 0,25 | 0,5 | 20 (95,2) | Na | |
| Voriconazole | 0,006–16 | 0,06 | 0,5 | 2 (9,5) | 7 (30,4) | |
| All Candida spp. (342) | Amphotericin B | 0.008–1 | 0.5 | 0.5 | na | 0 |
| Caspofungin | 0.002–1 | 0.06 | 0.125 | 0 | Na | |
| Fluconazole | 0.06–256 | 0.5 | 4 | 43 (12,6) | 56 (16,4) | |
| Itraconazole | 0.006–256 | 0.125 | 0.5 | 106 (31) | Na | |
| Voriconazole | 0.006–256 | 0.06 | 0.5 | 4 (1.2) | 34 (9,9) | |
SDD: susceptible dose dependence; na: breakpoint not available.
CLSI: Clinical and Laboratory Standards Institute; EUCAST: European Committee on Antimicrobial Susceptibility Testing.